论文信息 - KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. - 字舞流文

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

P. Ascierto | A. Ribas | M. Del Vecchio | W. Miller | M. Maio | M. Carlino | O. Hamid | M. Butler | P. Ferrucci | A. Joshua | Scott J. Diede | E. McWhirter | E. Gasal | R. Ghori | R. Zielinski | E. Croydon | E. Mcwhirter